Consumer group presses U.S. to authorize generic GLP-1s
Public Citizen has petitioned the Trump administration to take action under a federal law to allow generic competitors for GLP-1 drugs used in the treatment of obesity and diabetes. The consumer advocacy group argues that the prices of these drugs, sold by Novo Nordisk and Eli Lilly, are excessively high, making them unaffordable for many Americans.
The group points out that the high cost of these drugs has put a strain on both federal and state budgets. While recent deals with the Trump administration have aimed to make these drugs more accessible through Medicare and Medicaid, Public Citizen believes that the concessions made are not enough to address the issue of limited access.
One of the proposed solutions includes expanding coverage for these drugs under health care programs like Medicare and Medicaid, with a $50 per month copay for Medicare beneficiaries. While this may improve access for some individuals, there are concerns that not all Medicare and Medicaid plans will choose to participate if the increased use of these drugs leads to budgetary challenges.
Public Citizen’s petition highlights the need for more affordable options for GLP-1 drugs to ensure that all Americans have access to necessary treatments for obesity and diabetes. By allowing generic competitors to enter the market, the hope is to drive down prices and make these medications more accessible to those who need them.
For more in-depth analysis and exclusive content on this topic, readers can subscribe to STAT+. Unlock access to premium events, newsletters, and news alerts by subscribing to this platform.
